Equities analysts expect Concert Pharmaceuticals Inc (NASDAQ:CNCE) to post ($0.61) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Concert Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($0.62). Concert Pharmaceuticals reported earnings of ($0.60) per share during the same quarter last year, which suggests a negative year over year growth rate of 1.7%. The business is expected to report its next quarterly earnings report on Tuesday, May 1st.
On average, analysts expect that Concert Pharmaceuticals will report full-year earnings of ($2.35) per share for the current year, with EPS estimates ranging from ($2.67) to ($2.03). For the next fiscal year, analysts forecast that the firm will post earnings of ($2.41) per share, with EPS estimates ranging from ($2.67) to ($2.15). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Concert Pharmaceuticals.
Concert Pharmaceuticals (NASDAQ:CNCE) last announced its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.18) by ($0.08). Concert Pharmaceuticals had a net margin of 66.47% and a negative return on equity of 36.25%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $8.11 million.
In other Concert Pharmaceuticals news, Director Richard Aldrich sold 11,946 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $20.89, for a total value of $249,551.94. Following the completion of the sale, the director now directly owns 286,975 shares of the company’s stock, valued at $5,994,907.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the business’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total transaction of $34,188,112.40. The disclosure for this sale can be found here. Insiders sold 1,419,092 shares of company stock valued at $36,876,675 over the last three months. Insiders own 10.10% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new stake in shares of Concert Pharmaceuticals in the third quarter worth $153,000. Metropolitan Life Insurance Co. NY acquired a new stake in shares of Concert Pharmaceuticals in the fourth quarter worth $164,000. Alliancebernstein L.P. acquired a new stake in shares of Concert Pharmaceuticals in the second quarter worth $174,000. The Manufacturers Life Insurance Company lifted its stake in shares of Concert Pharmaceuticals by 1.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,052 shares of the biotechnology company’s stock worth $210,000 after buying an additional 287 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new stake in shares of Concert Pharmaceuticals in the fourth quarter worth $232,000. 70.32% of the stock is owned by institutional investors.
Concert Pharmaceuticals (NASDAQ:CNCE) opened at $23.31 on Tuesday. Concert Pharmaceuticals has a 1 year low of $11.88 and a 1 year high of $30.71. The company has a market cap of $549.93, a P/E ratio of 5.83 and a beta of 1.07.
TRADEMARK VIOLATION WARNING: This piece was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/03/13/zacks-brokerages-expect-concert-pharmaceuticals-inc-cnce-to-post-0-61-earnings-per-share.html.
About Concert Pharmaceuticals
Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.